Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_2:p10
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 2 (pt 10/13)
Character Range: 17501385–17504900

to 1 month may be requested through the Online PBS Authorities system or by calling Services Australia.
                Methadone                  Authority requests extending treatment duration beyond 1 month may be requested through the Online PBS Authorities system or in writing and must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).
V11697          Hydromorphone              Authority requests extending treatment duration up to 1 month may be requested through the Online PBS Authorities system or by calling Services Australia.
                Morphine                   Authority requests extending treatment duration beyond 1 month may be requested through the Online PBS Authorities system or in writing and must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).
V11753          Buprenorphine              Authority requests for treatment duration up to 1 month may be requested through the Online PBS Authorities system or by calling Services Australia.
                Morphine                   Authority requests extending treatment duration beyond 1 month may be requested through the Online PBS Authorities system or in writing and must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).
                Oxycodone
                Oxycodone with naloxone
V14842          Desmopressin               No more than twice the maximum quantity will be authorised.
V14945          Desmopressin               No increase in the maximum quantity or number of units may be authorised.
V14972          Desmopressin               No more than twice the maximum quantity will be authorised.
V15025          Desmopressin               No increase in the maximum quantity or number of units may be authorised.
V15303          Tafamidis                  If heart failure has worsened to NYHA Class III/IV since the last authority application, no more than 2 repeat prescriptions must be prescribed.
V15456          Midazolam                  At the time of the authority application, practitioners should request the appropriate quantity to cater for the patient's circumstances.
                                           Up to a maximum of 10 syringes for each prescription can be authorised for patients with high frequency seizures.
V15457          Midazolam                  At the time of the authority application, medical practitioners should request the appropriate quantity to cater for the patient's circumstances.
                                           Up to a maximum of 10 syringes for each prescription can be authorised for patients with high frequency seizures.
V15527          Nivolumab                  An increase in repeat prescriptions, up to a value of 11, may only be sought where the prescribed dosing is 240 mg administered fortnightly.
V15818          Trastuzumab emtansine      Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg
V15819          Trastuzumab emtansine      Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg
V15820          Trastuzumab                Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg
V15826          Trastuzumab deruxtecan     Increased maximum amounts may only be authorised where